Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control study

Area of Science:

• Neuroscience
• Immunology
• Biochemistry

Background:

• Oligodendrocytes are crucial for myelin regeneration in multiple sclerosis (MS).
• Fibroblast growth factor-2 (FGF-2) and platelet-derived growth factor-A (PDGF-AA) influence oligodendrocyte function.
• Understanding the role of these growth factors in MS pathogenesis is essential.

Purpose of the Study:

• To measure serum and cerebrospinal fluid (CSF) levels of FGF-2 and PDGF-AA in patients with relapsing-remitting multiple sclerosis (RR-MS).
• To compare these levels with those in control subjects.
• To investigate the correlation of these factors with disease duration and severity.

Main Methods:

• Serum and CSF samples were collected from 23 RR-MS patients during relapse and remission phases, and from 23 controls.
• Enzyme-linked immunosorbent assay (ELISA) was used to quantify FGF-2 and PDGF-AA.
• Statistical analyses included Wilcoxon, Mann-Whitney U-test, and Spearman's rank correlation.

Main Results:

• Serum FGF-2 showed a trend towards higher levels during MS relapse (P=0.052).
• CSF PDGF-AA significantly negatively correlated with disease duration (r=-0.58, P=0.004).
• CSF PDGF-AA levels were significantly lower in patients with MS duration ≥2 years compared to controls (P<0.05).

Conclusions:

• CSF PDGF-AA is associated with the duration of multiple sclerosis.
• Serum and CSF levels of FGF-2 and PDGF-AA appear to be weak indicators of MS disease severity.